Steven A. Stacker
Ludwig Institute for Cancer Research
Royal Melbourne Hospital
Victoria
Australia
Name/email consistency: high
- From anti-angiogenesis to anti-lymphangiogenesis: emerging trends in cancer therapy. Stacker, S.A., Achen, M.G. Lymphat. Res. Biol (2008)
- Current strategies for modulating lymphangiogenesis signalling pathways in human disease. Stacker, S.A., Hughes, R.A., Williams, R.A., Achen, M.G. Curr. Med. Chem. (2006)
- Molecular targeting of lymphatics for therapy. Stacker, S.A., Hughes, R.A., Achen, M.G. Curr. Pharm. Des. (2004)
- Lymphangiogenic growth factors as markers of tumor metastasis. Stacker, S.A., Williams, R.A., Achen, M.G. APMIS (2004)
- The role of tumor lymphangiogenesis in metastatic spread. Stacker, S.A., Baldwin, M.E., Achen, M.G. FASEB J. (2002)
- The 3T3-L1 fibroblast to adipocyte conversion is accompanied by increased expression of angiopoietin-1, a ligand for tie2. Stacker, S.A., Runting, A.S., Caesar, C., Vitali, A., Lackmann, M., Chang, J., Ward, L., Wilks, A.F. Growth. Factors (2000)
- The vascular endothelial growth factor family: signalling for vascular development. Stacker, S.A., Achen, M.G. Growth. Factors (1999)
- Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. Stacker, S.A., Stenvers, K., Caesar, C., Vitali, A., Domagala, T., Nice, E., Roufail, S., Simpson, R.J., Moritz, R., Karpanen, T., Alitalo, K., Achen, M.G. J. Biol. Chem. (1999)
- A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability. Stacker, S.A., Vitali, A., Caesar, C., Domagala, T., Groenen, L.C., Nice, E., Achen, M.G., Wilks, A.F. J. Biol. Chem. (1999)
